Altis Labs
Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints
Altis Labs announced $25M in Series A financing on September 17, 2026. Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.
Round details
The financing includes backing from OrbiMed, Qiming Venture Partners USA, Innovation Endeavors, Cancer Breakthrough Fund. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: $25M
- Headquarters: Toronto, Canada
How the company plans to use the capital
Altis will expand its AI models across additional cancer types, scale commercial deployments with biopharmaceutical partners, and work to establish AI endpoints as a standard for oncology trials.
Why this matters for GTM teams
The round points to increasing investment in AI systems that improve trial decisions by connecting medical imaging with longitudinal outcomes and clinical evidence.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Altis Labs Series A announcement.
Company Info
Investors (4)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started